Madrigal Pharmaceuticals (MDGL) had the best year in 2017 by a large-cap US stock in 2017, returning 514%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Madrigal Pharmaceuticals (MDGL) | 2017 | 513.98% |
argenx NV ADR (ARGX) | 2017 | 252.74% |
Alnylam Pharmaceuticals (ALNY) | 2017 | 233.03% |
Roku (ROKU) | 2017 | 228.14% |
BeiGene (ONC) | 2017 | 219.01% |
Huazhu (HTHT) | 2017 | 180.5% |
Leonardo DRS, Inc Common Stock (DRS) | 2017 | 154.54% |
Block (XYZ) | 2017 | 150.87% |
Corcept Therapeutics (CORT) | 2017 | 147.74% |
Arista Networks (ANET) | 2017 | 141.52% |
Arrowhead Pharmaceuticals (ARWR) | 2017 | 135.9% |
NRG Energy (NRG) | 2017 | 132.56% |
Insmed (INSM) | 2017 | 132.17% |
Align Technology (ALGN) | 2017 | 130.27% |
Wayfair (W) | 2017 | 130.07% |
Take-Two Interactive Software (TTWO) | 2017 | 122.45% |
NVR (NVR) | 2017 | 112.62% |
Sociedad Quimica y Minera de Chile SA ADR B (SQM) | 2017 | 110.33% |
XPO Logistics (XPO) | 2017 | 109.35% |
First Solar (FSLR) | 2017 | 107.05% |
Vertex Pharmaceuticals (VRTX) | 2017 | 101.34% |
Exelixis (EXEL) | 2017 | 100.79% |
Ascendis Pharma A-S (ASND) | 2017 | 100.6% |
Neurocrine Biosciences (NBIX) | 2017 | 100.03% |
MercadoLibre (MELI) | 2017 | 98.47% |
Large-cap stocks are treated as having a market cap of $10B+.